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Background: Though Mica, a thin and sheet like mineral, has been used as a mineral medicine for treatment of
bleeding, dysentery and inflammation in traditional medicine including Ayurveda, the biological evidences of Mica
were not clearly elucidated so far. Thus, in the present study, the antitumor mechanism of particled Mica (STB-HO)
was examined in colorectal cancers.
Methods: Athymic nude mice were inoculated with HCT116 colon cancer cells and orally administered STB-HO
daily for 41 days, and HCT116 and human umbilical vein endothelial cells (HUVECs) were treated with STB-HO for 0 ~
24 hours to perform immunoblotting, cytotoxicity assay, FACs analysis and measurement of matrix metalloproteinase 9
(MMP-9) secretion and other experiments. Significant differences of all date were evaluated using Student’s t-test and a
Turkey-Kramer multiple-comparison post test.
Results: STB-HO significantly suppressed the tumor volume and weight in athymic nude mice inoculated with HCT116
cells at a dose of 100 mg/kg. Thus, the in vivo antitumor mechanism of STB-HO was to elucidated in vitro as well. STB-
HO exerted cytotoxicity in HCT116, SW620 and HCT15 colorectal cancer cells. Also, STB-HO increased G1 cell population
in a time and concentration dependent manner, enhanced the expression of p21, p27, p53 as cyclin dependent kinase
(CDK) inhibitors, attenuated the expression of proliferating cell nuclear antigen (PCNA) and cyclin D1 and also reduced
the production of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP-9) in HCT116 cells.
Consistently, STB-HO suppressed the phosphorylation of VEGFR2 in HCT116, SW620 and HCT15 cells. Also, STB-HO
inhibited the VEGF mediated proliferation and also attenuated the phosphorylation of VEGFR2 and Akt in human
umbilical vein endothelial cells (HUVECs).
Conclusions: Collectively, these findings suggest that STB-HO has chemopreventive potential via G1 arrest and
inhibition of proliferation and VEGFR2 in HCT116 colorectal cancer cells.
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Colorectal cancer (CRC) is one of the leading causes of
mortality in the western world. Chemotherapy including
5-fluorouracil (5-FU) therapy and surgical resection are
well known methods for colon cancer treatment [1].
However, the side effects are induced by chemotherapy
such as oral mucositis, diarrhea, neuropathy, anemia and
alopecia [2]. Thus, recently natural products [3] and com-
pounds [4-6] were reported to have antitumor effects in
colorectal cancers alone or in combination with anticancer
agents [7] with low toxicity. Also, Hu et al. suggested that
among men and women taking vitamin and mineral sup-
plements for more than 5 years, significant inverse associ-
ations with colon cancer were most pronounced among
women with distal colon cancer [8]. Similarly, there are
evidences that mineral selenium has antitumor activity in
colon cancers [9-12].
The Mica group of sheet silicate minerals are generally
classified as trioctahedral Mica including Biotite, Lepido-
lite, Muscovite, Phlogopite, Zinnwaldite and interlayer de-
ficient Mica [13]. Mica has been used for decoration
and treatment for bleeding, dysentery and inflamma-
tion in traditional medicine including Ayurveda for
ages. Nasrin et al. showed no toxicity of Chondrokola
Rosh, a traditional metallic Ayurvedic preparation, in-
cluding various roasted metals (Hg and Cu), non-metal
(sulphur and Mica) and medicinal herbs [14]. Also Mica
was known to protect gastric mucosa by improving
blood flow and inflammatory response [15] as well as
suppress gastric cancer via regulation of p16 and Bcl-2
in rats [16], indicating Mica can be used as a medicine
[17]. Thus, in the present study, antitumor mechanism
of particled Mica (STB-HO) was examined in vitro in
HCT116 colorectal cancer and human umbilical vein
endothelial cells (HUVECs) and athymic nude mice
inoculated with HCT116 cells.Methods
Chemicals and reagents
STB-HO (particled Mica; Korea Patent Registration; 10–
0454200) was supplied from Seobong Biobestech Com-
pany (Seoul, Republic of Korea). SW620, HCT116 and
HCT15 human colorectal adenocarcinoma cells from the
American Type Culture Collection (ATCC, Manassas, VA,
USA) were maintained in RPMI 1640 supplemented with
fetal bovine serum (FBS), liquid gentamicin reagent solu-
tion, penicillin and streptomycin (PEST), and trypsin
EDTA were purchased from Gibco (Carlsbad, CA, USA).
Human umbilical vein endothelial cells (HUVECs) cells
from the American Type Culture Collection (Manassas,
VA, USA) were maintained in M199 supplemented with
20% fetal bovine serum (FBS), liquid gentamicin reagent
solution, penicillin and streptomycin (PEST), 3 ng/mlbFGF, 5 units/ml heparin. Enhanced chemiluminescence
(ECL) Western blotting detection reagents and Hyperfilm
ECL were from Amersham-Pharmacia Korea (Seoul,
Korea). Anti-rabbit IgG heavy and light chain-specific
(rabbit, mouse) peroxidase conjugates and antibody
against p21, p27, p53, pp53, cyclin D1, pAKT, AKT, PI3K
and PCNA were purchased from Cell signaling technology
(Denver, MA, USA). Antibodies of VEGFR2 and pVE
GFR2 were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). β-actin was purchased from
Sigma Chemical Co. (St. Louis, MO, USA). VEGF and
MMP-9 ELISA kit were purchased from Invitrogen
(Carlsbad, CA, USA). Human recombinant VEGF was
purchased from R&D systems (Minneapolis, MN, USA).
Cell Proliferation ELISA kit was purchased from
ROCHE (F. Hoffmann-La Roche Ltd, Switzerland). All
other reagents used were purchased from Sigma Chemical
(St Louis, MO, USA).Cell culture
SW620(ATCC CCL-227™), HCT116(ATCC CCL-247™)
and HCT15 cells(ATCC CCL-225™) were seeded onto
100 mm Falcon plates at 2 × 106 cells/mL in RPMI 1640
supplemented with 10% FBS and 1% penicillin/strepto-
mycin. The cells were cultured at 37°C in a humidified
atmosphere containing 5% CO2 to 60–80% confluence
and then used for Western blot analysis. STB-HO was
treated to various human colon cancer cells for 24, 48, 72
and 96 h. HUVECs were maintained in M199 plus 20%
heat-inactivated fetal bovine serum (FBS), 3 ng/ml bFGF,
5units/ml heparin, 100 units/ml antibiotic-antimycotic so-
lution (complete M199) in 0.1% gelatin coated flasks and
incubated at 37°C in a humidified atmosphere containing
5% CO2. Once confluent, the cells were detached by
trypsin-EDTA solution and used in experiments from the
third to the sixth passages.Cytotoxicity assay
Cytotoxicity of STB-HO was evaluated by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium brom-
ide (MTT) assay. Briefly, HUVECs were seeded onto
0.1% gelatin coated 96-well microplates at a density of
5×103 cells per well and treated with various concen-
trations of STB-HO (0, 15.63, 31.25, 62.5,125, 250, 500,
or 1000 μg/ml) for 48 h. After indicated incubation
times, MTT (1 mg/ml) (Sigma Chemical Co., St. Louis,
MO) solution was added for 2 h and MTT lysis buffer
(20% SDS and 50% dimethylformamide) was then
added for overnight. Optical density (OD) was mea-
sured using a microplate reader (TECAN, Austria) at
570 nm. Cell viability was calculated as a percentage of
viable cells in STB-HO treated group versus untreated
Figure 1 Effect of STB-HO on the tumor weight and growth in
athymic nude mice inoculated by HCT116 cells. From three days
after HCT116 cell inoculation, STB-HO (50 and 100 mg/kg body
weight) was orally administered daily. (A) Photographs of dissected
tumors in mice. (B) Tumor growth in a time course. (C) Final tumor
weight at the termination of experiment. Values were means ±SD,
n=6. *p < 0.05 and ***p<0.001 compared to untreated control.
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Cell viability %ð Þ ¼ O:D: STB−HOð Þ−O:D: Blankð Þ½ 
O:D: Controlð Þ−O:D: Blankð Þ½ 
 100
Proliferation assay
Cell proliferation in HCT116 cells with STB-HO was
evaluated as described by using Cell proliferation ELISA
kit (Roche, Swiss) according to the manufacturer’s
instructions. Briefly, after 48 h treatment of STB-HO,
the cells were added by 10 μl/well of bromodeoxyuridine
(BrdU) solution and reincubated for 2 h at 37°C. Then,
BrdU solution was removed and 200 μl of FixDenat was
added to each well. After incubation for 30 min at room
temperature, FixDenat solution was removed and 100 μl
of anti-BrdU-POD working solution was added to each
well. After washing with PBS three times, 100 μl of sub-
strate solution was added to each well and the optical
density was measured at 450 nm using microplate reader
(Molecular Devices Co., Sunnyvale, CA, USA). All sam-
ples were prepared in triplicates and the assay was re-
peated at least three times.
Cell cycle analysis
HCT116 cells were treated with STB-HO (250 and
500 μg/ml) for 24, 48 and 72 h. The cells were fixed in
75% ethanol at −20°C and treated with RNase A (10 mg/
ml) for 1 h at 37°C, stained with propidium iodide (PI)
(50 μg/ml) and analyzed for the DNA content by
FACSCalibur (Becton–Dickinson, Franklin Lakes, NJ,
USA) using CellQuest Software (BD Bio-sciences, San
Jose, CA, USA).
Western blotting
Cells (5×106 cells) treated with STB-HO were lyzed by
using lysis buffer (50 mM Tris–HCl, pH 7.4, 300 mM
NaCl, 0.5% Triton X-100, 0.1% SDS, 5 mM EDTA, and
protease inhibitor cocktail). The extracts were incubated
on ice for 30 min, and then centrifuged at 13,000×g for
30 min at 4°C and the supernatants were collected for
western blotting. Protein concentrations were deter-
mined by Bradford assay (Bio-Rad), and equal amounts
of proteins (30 μg) were separated by electrophoresis
sodium dodesyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) and transferred to PVDF membranes
(Amersham Biosciences, Piscataway, NJ, USA). The
membranes were blocked with 5% skim milk in Tris-
buffered saline containing 0.1% Tween 20 for 2 h at
room temperature. The membranes were probed over-
night at 4°C with mouse anti-human β-actin (1:1000;
Sigma Aldrich, St. Louis, MO, USA), anti-human pAKT,
AKT, p21, p27, p53, pp53, cyclin D1, PCNA and PI3K
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VEGFR2 and pVEGFR2 (1:500; Santa Cruz Biotechnology,
CA, USA) followed by washing and incubation with HRP
conjugated secondary antibody (AbD Serotec, Raleigh,
NC, USA). Immunoreactive bands were visualized using
the ECL system (Amersham-Pharmacia, Seoul, Korea).
Measurement of VEGF and MMP-9 production by ELISA
VEGF and MMP-9 levels in HCT116 cells treated with
STB-HO were measured using VEGF and MMP-9Figure 2 Effect of STB-HO on the morphology of HCT116, SW620 and
treated to HCT116, SW620 and HCT15 cells for 96 h, and its cell images we
with STB-HO for 48 h and cell proliferation was measured by using BrdU pELISA kit (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. Briefly, the culture
supernatants was added onto a 96-well microplate, and
incubated for 2 h at room temperature. The plate was
then washed four times with washing buffer and 100 μl
of biotin conjugate was placed to each well for 1 h at
room temperature. After washing four times with wash-
ing buffer, 100 μl of the stabilized chromogen was placed
to each well and incubated for 30 min at room
temperature in dark. Finally, 100 μl of stop solution wasHCT15 cells and the proliferation of HCT116 cells. (A) STB-HO was
re taken by using microscope (X200). (B) HCT116 cells were treated
roliferation ELISA kit (Roche, Swiss).
Figure 3 Effect of STB-HO on G1 arrest and cell cycle related genes in HCT116 cells. (A) Cells were treated with STB-HO (0, 250 or 500 μg/
ml) for 24, 48 and 72 h. Cell cycle distribution was analyzed by flow cytometry. Bar graphs represent the percentage of the sub-G1 apoptotic
DNA fraction. Data are presented as means ± S.D. *p < 0.05 and ***p < 0.001 compared between each time’s control and STB-HO (250 or
500 μg/ml) treated groups. (B) HCT116 cells were treated with or without STB-HO (0, 250 or 500 μg/ml) for 24 h. Cell lysates were prepared and
subjected to Western blotting to determine the expression of p21, p27, p53, pp53, Cyclin D1, PCNA and β-actin. Band density of β-actin, p21, p27,
pp53, PCNA and Cyclin D1 were quantified using Gelpro analyzer (Media Cybernetics, Bethesda, MD, USA).
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at 450 nm using microplate reader (Molecular Devices
Co., Sunnyvale, CA, USA).
HCT116 xenograft model
Four-week-old female BALB/c athymic nude mice (18 ±
3 g) were purchased from Chung-Ang Laboratory Animals
(Seoul, Korea) and housed in animal facility at 22 ± 3°C
and 60 ± 10% humidity with light-controlled (12 h, 07:00–
19:00) environment. All materials including bedding
and feed were sterilely cleaned by UV rays for 30 min
before treatment to the mice. The animal study was
conducted under the guidelines approved by Institu-
tional Animal Care and use Committee, Kyung Hee
University [KHUASP(SE)-11-005] as previously de-
scribed with minor modifications [18]. Briefly, 2 × 10 6
of HCT116 cells were mixed with Matrigel (Becton
Dickinson, 50% in 100 μl) and injected subcutaneously
into the right flank of 6-week-old male BALB/cFigure 4 Effect of STB-HO on VEGF production and MMP-9 secretion
(0, 250 or 500 μg/ml) for 48 h. (A) STB-HO inhibits vascular endothelial gro
removal of the supernatant, HCT116 cells were washed by PBS. The cells w
measured by ELISA. (B) STB-HO inhibits matrix metalloproteinase (MMP-9) p
means ± S.D. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to untreaathymic nude mice (Chung-Ang Laboratory Animals,
Seoul, Korea)) for 3 groups (Control and two STB-HO
treated groups). After 1 week adaptation, the animals
were assigned to four groups (n = 6): negative control
(vehicle (saline) + HCT116 inoculation), STB-HO50
(50 mg/kg+ HCT116 inoculation), and STB-HO100
(100 mg/kg+ HCT116 inoculation). Everyday STB-HO
dissolved in saline was orally treated to the athymic
nude mice for 41 days during experiment period.
Tumor size was monitored twice a week with a caliper,
and tumor volume was also calculated as described
[19]. At the end of animal study, tumors were dis-
sected, weighed and photographed.Data analyses
Data were shown as means ± SE. Significant differences
were evaluated using Student’s t-test and a Turkey-
Kramer multiple-comparison post test.in HCT116 cells. HCT116 Cells were treated with or without STB-HO
wth factor (VEGF) production. VEGF level was measured by ELISA. After
ere cultured in completed RPMI media for 48 h. Then VEGF level was
roduction. MMP-9 level was measured by ELISA. Data are presented as
ted control.
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STB-HO suppresses tumor growth in HCT116 xenograft
model
As shown in Figure 1B, STB-HO suppressed the growth
of HCT116 cancer cells inoculated in BALB/c athymicFigure 5 Effect of STB-HO on pVEGFR2, PI3K and Akt in colon cancer
cancer cells by Western blotting. (B) STB-HO (0, 250 or 500 μg/ml) was trea
blotting was performed to determine the expression of pVEGFR2, VEGFR2,nude mice at the doses of 50 and 100 mg/kg without af-
fecting body weight (Data not shown). Consistently,
Treatment of STB-HO reduced the tumor weight in a
dose dependent manner compared to untreated group
following animal sacrifice, but statistical significance wascells. (A) Basal expression of pVEGFR2 was confirmed in various colon
ted in HCT15, SW620 and HCT116 colon cancer cells for 24 h. Western
PI3K, pAKT, AKT and β-actin in STB-HO treated colon cancer cells.
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treated group (Figure 1A, C).
STB-HO inhibits cell proliferation in human colorectal
cancer cell lines
We first investigated whether STB-HO can suppress the
proliferation of human colon cancer cell lines. After
treatment with STB-HO in human colon cancer cell
lines for 96 h, cell morphology was observed using
microscope. As shown Figure 2A, STB-HO significantly
suppressed cell proliferation in human colon cancer
cells. Especially, the suppression of cell proliferation by
STB-HO treatment was more effective in HCT 116 cancer
cells compared to other colorectal cancer cells such as
SW620 and HCT15 cells. Consistently, BrdU assay re-
vealed, as shown in Figure 2B, the proliferation of HCT116
cells was decreased in a concentration dependent manner
by STB-HO treatment, implying that STB-HO inhibits the
proliferation of colorectal cancer cells.Figure 6 Effect of STB-HO on the viability and VEGF mediated prolife
to HUVECs and cytotoxicity of STB-HO in HUVECs was measured by MTT as
heat-inactivated FBS, heparin (5 units/ml) and VEGF 10 ng/ml for 48 h, and
absorbance was measured by ELISA reader. Data were presented as means
treated control. All samples were prepared in triplicates and the assay wasSTB-HO induces G1 arrest in HCT116 colorectal
cancer cells
Cell cycle analysis was performed to find out the effect
of STB-HO in HCT116 cancer cells. STB-HO signifi-
cantly increased G1 population in HCT116 cells in a
time dependent manner (Figure 3A). One day after STB-
HO treatment, the expression of p21, p27 and pp53 as
CDK inhibitors was significantly increased in HCT116
cells (Figure 3B). In addition, STB-HO suppressed the
expression of cyclin D1 and PCNA which are regulating
cell cycle (Figure 3B). These data indicate that STB-HO
induces G1 arrest which is crucial to inhibit proliferation
and induce apoptosis in HCT116 colorectal cancer cells.
STB-HO suppresses the production of VEGF and MMP-9 in
HCT 116 colorectal cancer cells
We also examined the effect of STB-HO on the produc-
tion of VEGF and MMP-9 which are closely associated
with metastasis and angiogenesis [20,21]. HCT 116 cancerration of HUVECs. (A) Various concentrations of STB-HO were treated
say. (B) HUVECs were exposed to STB-HO in M199 containing 1%
the VEGF mediated proliferation was assessed by MTT assay. The
± S.D. * p < 0.05, ** p < 0.01 and *** p < 0.001 compared with VEGF
repeated at least three times.
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MMP-9 levels were measured by ELISA. VEGF and
MMP-9 production that are associated with angiogenesis
and metastasis was significantly decreased in a dose
dependent manner in HCT 116 colon cancer cells by
STB-HO as shown in Figure 4A and Figure 4B. Also,
though further changing medium one day later, the
production of VEGF and MMP-9 was still suppressed in
HCT 116 cancer cells, implying that STB-HO may exert
anti-angiogenic activity in cancer cells.STB-HO suppresses VEGFR2 and PI3K/Akt signaling in
colorectal cancer cells
VEGF receptor (VEGFR) is crucial to promote tumor
progression, angiogenesis and proliferation by binding to
VEGF. The basal expression of VEGFR-2 was confirmed
in colorectal cancer cells such as SW620, HCT116 and
HCT15 (Figure 5A). We also found that the phosphoryl-
ation of pVEGFR2, PI3K and pAKT was attenuated in
three colon cancer cells by STB-HO (Figure 5B), demon-
strating STB-HO can abrogate the activity of proliferation
in cancer cells via suppression of pVEGFR2, PI3K and
pAKT.Figure 7 Effect of STB-HO on pVEGFR2, PI3K and Akt in HUVECs. HUV
and then treated with various concentrations of STB-HO (0, 250 or 500 μg/
units/ml heparin for 10 min, 30 min, 1 h, 2 h, and 24 h. The cells were harv
expression of pVEGFR2, VEGFR2, pAKT, AKT and β-actin.STB-HO inhibits VEGF mediated proliferation and
phosphorylation of VEGFR2 and Akt in HUVECs
As shown in Figure 6A, MTT assay revealed that STB-
HO did not show any cytotoxicity in HUVECs as a nor-
mal cell line. Also, to confirm antiangiogenic activity of
STB-HO in HUVECs, proliferation assay was performed
in VEFG treated HUVECs by MTT assay. As shown in
Figure 6B, STB-HO inhibited VEGF-induced proliferation
of HUVECs in a dose dependent manner at nontoxic con-
centrations in HUVECs. In addition, as shown in Figure 7,
STB-HO suppressed the phosphorylation of VEGFR-2 and
Akt in HUVECs compared to untreated control.
Discussion
There are evidences that minerals have antitumor activity
in several cancers. For instances, arsenic trioxide (As2O3)
was known to treat breast cancer [22] and colon cancer
cells [23,24], selenium (Se) was reported to have antitumor
potential in several cancers such as colon [25,26], prostate
[27,28], zinc (Zn) was reported to have potential thera-
peutic for chemoresistant ovarian cancer [29] and also
cadmium (Cd) induced mitogenic signaling in breast
cancer cell by an ER alpha-dependent mechanism [30].
Similarly, in the present study, mineral Mica (STB-HO)ECs were starved for 24 h in M199 containing 1% heat-inactivated FBS
ml) in M199 containing 1% heat-inactivated FBS, 10 ng/ml VEGF and 5
ested and western blotting was performed to determine the
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STB-HO exerted anti-proliferative activity in HCT116,
SW620 and HCT15 colorectal cancer cells, HCT116 cells
are were more susceptible to STB-HO compared to two
other colon cancer cells, since they are positive for
transforming growth factor beta 1 (TGF beta 1) and beta 2
(TGF beta 2) expression with a mutation in codon 13 of
the ras protooncogene [31].
Also, STB-HO increased G1 cell population in a time
and concentration dependent manner and enhanced the
expression of p21, p27, p53 as cyclin dependent kinase
(CDK) inhibitors [32-34], attenuated the expression of
proliferating cell nuclear antigen (PCNA) and cyclin D1,
implying G1 arrest leading to cell death by STB-HO in
HCT116 cells. Furthermore, STB-HO attenuated the ex-
pression of survival gene PCNA and reduced typical
angiogenesis marker VEGF production in HCT116 cells,
indicating anti-proliferative and anti-angiogenic activity
of STB-HO in HCT116 cells.
VEGF is an important signaling protein involved in
both vasculogenesis and angiogenesis. As an essential re-
ceptor protein tyrosine kinase propagating cellular signal
transduction processes, VEGFR-2 is a central target for
drug discovery against tumor-associated angiogenesis [35].
Consistently, STB-HO suppressed the phosphorylation of
VEGFR2 in HCT116, SW620 and HCT15 cells and also
inhibited the VEGF mediated proliferation as well as
attenuated the phosphorylation of VEGFR2 and Akt in hu-
man umbilical vein endothelial cells (HUVECs), strongly
demonstrating anti-angiogenic activity via inhibition of
VEGFR2 signaling. Consistently, ELISA revealed that
STB-HO reduced the production of VEGF and MMP-9 in
HCT116 cells. Nevertheless, it was noteworthy that STB-
HO suppressed the tumor volume and weight in athymic
nude mice inoculated with HCT116 cells at a dose of 50
and 100 mg/kg through two animal studies. However, the
in vitro effective concentration was high because of poor
solubility of STB-HO in cell culture study, which should
be improved by nanoparticle method, synthesis or new
dilution methods in the near future.
Conclusions
Mineral Mica (STB-HO) showed cytotoxicity in colorectal
cancer cells, increased G1 arrest and, reduced VEGF pro-
duction in HCT116 colorectal cancer cells, attenuated the
phosphorylation of VEGFR2 and Akt in HUVECs and
suppressed the tumor volume and weight in athymic nude
mice inoculated with HCT116 cells. Collectively, these
findings suggest that STB-HO has chemoprevntive poten-
tial via G1 arrest and inhibition of proliferation and
VEGFR2 in HCT116 colorectal cancer cells.
Abbreviations
HUVECs: Human umbilical vein endothelial cells; MMP-9: Matrix
metalloproteinase 9; CDK: Cyclin dependent kinase; PCNA: Proliferating cellnuclear antigen; VEGF: Vascular endothelial growth factor; MTT: 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide;
BrdU: Bromodeoxyuridine; VEGFR: VEGF receptor; ELISA: Enzyme-linked
immunosorbent assay enzyme-linked immunospecific assay.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SYC carried out the study and wrote the manuscript. HJL carried out the
study, designed the experiments and helped conceive the study. SMC and
BLK carried out the study and contributed animal model. YKJ contributed
reagents and materials. SHK conceived and designed experiments and
revised the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by National Foundation of Korea (NRF) grant
funded by the Korea government [MEST] (No. 2012–0005755).
Author details
1Cancer Preventive Material Development Research Center, College of
Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu,
130-701, Seoul, South Korea. 2SeoBong Biobestech Co, 831 Yeoksam-dong,
Gangnam-gu, Ltd.Hye Cheon Bldg #401, 135-080, Seoul, Republic of Korea.
Received: 20 December 2012 Accepted: 9 July 2013
Published: 24 July 2013
References
1. Honey Sinha VR: Critical aspects in rationale design of fluorouracil-based
adjuvant therapies for the management of colon cancer. Crit Rev Ther
Drug Carrier Syst 2012, 29(2):89–148.
2. Hazlewood B: 5-FU and leucovorin: unexpected side effects. Oncol Nurs
Forum 1990, 17(5):762.
3. Rajamanickam S, Agarwal R: Natural products and colon cancer: current
status and future prospects. Drug Dev Res 2008, 69(7):460–471.
4. Kang YJ, Park KK, Chung WY, Hwang JK, Lee SK: Xanthorrhizol, a natural
sesquiterpenoid, induces apoptosis and growth arrest in HCT116 human
colon cancer cells. J Pharmacol Sci 2009, 111(3):276–284.
5. Imai M, Kikuchi H, Denda T, Ohyama K, Hirobe C, Toyoda H: Cytotoxic
effects of flavonoids against a human colon cancer derived cell line,
COLO 201: a potential natural anti-cancer substance. Cancer Lett 2009,
276(1):74–80.
6. Reyes-Zurita FJ, Rufino-Palomares EE, Lupianez JA, Cascante M: Maslinic
acid, a natural triterpene from Olea europaea L., induces apoptosis in
HT29 human colon-cancer cells via the mitochondrial apoptotic
pathway. Cancer Lett 2009, 273(1):44–54.
7. Norwood AA, Tucci M, Benghuzzi H: A comparison of 5-fluorouracil and
natural chemotherapeutic agents, EGCG and thymoquinone, delivered
by sustained drug delivery on colon cancer cells. Biomed Sci Instrum 2007,
43:272–277.
8. Hu J, Morrison H, Mery L, DesMeules M, Macleod M: Diet and vitamin or
mineral supplementation and risk of colon cancer by subsite in Canada.
Eur J Cancer Prev 2007, 16(4):275–291.
9. Connelly-Frost A, Poole C, Satia JA, Kupper LL, Millikan RC, Sandler RS:
Selenium, folate, and colon cancer. Nutr Cancer 2009, 61(2):165–178.
10. Kucharzewski M, Braziewicz J, Majewska U, Gozdz S: Selenium, copper, and
zinc concentrations in intestinal cancer tissue and in colon and rectum
polyps. Biol Trace Elem Res 2003, 92(1):1–10.
11. Nano JL, Czerucka D, Menguy F, Rampal P: Effect of selenium on the
growth of three human colon cancer cell lines. Biol Trace Elem Res 1989,
20(1–2):31–43.
12. Lee YK, Park SY, Kim YM, Kim DC, Lee WS, Surh YJ, Park OJ: Suppression of
mTOR via Akt-dependent and -independent mechanisms in selenium-
treated colon cancer cells: involvement of AMPKalpha1. Carcinogenesis
2010, 31(6):1092–1099.
13. Hansma HG: Possible origin of life between mica sheets. J Theor Biol 2010,
266(1):175–188.
14. Nasrin S, Bachar SC, Choudhuri MS: Toxicological studies of "Chondrokola
Rosh", an Ayurvedic preparation on liver function tests of rats. Afr J Tradit
Complement Altern Med 2011, 8:170–174. 5 Suppl.
Cho et al. BMC Complementary and Alternative Medicine 2013, 13:189 Page 11 of 11
http://www.biomedcentral.com/1472-6882/13/18915. Zhu FS, Si JM, Wang LJ, Wang DF, Chen P: Effect of mica monomer
powder on chief and parietal cells as well as G and D cells in gastric
mucosa of chronic atrophic gastritis in rats. Chin J Integr Med 2008,
14(2):111–116.
16. Zhu FS, Si JM, Wang LJ, Wang DF, Chen P: Effect of mica granule on the
expression of gene-protein associated with cancer in gastric mucosa
tissue of chronic atrophic gastritis rats. Zhongguo Zhong Yao Za Zhi 2006,
31(4):312–316.
17. Jang HD, Kim JD, Hong JW, Yoo JS, Kim HJ, Shin SO, Hwang Y, Zhou TX,
Chen YJ, Cho JH, Jeong YK, Kim IH: Effects of Dietary Biotite Powder on
Growth Performance, Changes in blood immune and stress related
parameters, and fecal malodor gas emission in growing pigs. J of Animal
Science & Technology 2008, 50(3):321–330.
18. Lee HJ, Seo NJ, Jeong SJ, Park Y, Jung DB, Koh W, Lee HJ, Lee EO, Ahn KS,
Ahn KS, Lü J, Kim SH: Oral administration of penta-O-galloyl-β-D-glucose
suppresses triple-negative breast cancer xenograft growth and
metastasis in strong association with JAK1-STAT3 inhibition.
Carcinogenesis 2011, 32(6):804–811.
19. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY: An
armed oncolytic adenovirus system, ZD55-gene, demonstrating potent
antitumoral efficacy. Cell Res 2003, 13(6):481–489.
20. Klein G, Vellenga E, Fraaije MW, Kamps WA, De Bont ES: The possible role
of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute
leukemia. Crit Rev Oncol Hematol 2004, 50(2):87–100.
21. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T: Regulation of
matrix metalloproteinases: an overview. Mol Cell Biochem 2003,
253(1–2):269–285.
22. Xia J, Li Y, Yang Q, Mei C, Chen Z, Bao B, Ahmad A, Miele L, Sarkar FH,
Wang Z: Arsenic Trioxide Inhibits Cell Growth and Induces Apoptosis
through Inactivation of Notch Signaling Pathway in Breast Cancer.
Int J Mol Sci 2012, 13(8):9627–9641.
23. Stevens JJ, Graham B, Walker AM, Tchounwou PB, Rogers C: The effects of
arsenic trioxide on DNA synthesis and genotoxicity in human colon
cancer cells. Int J Environ Res Public Health 2010, 7(5):2018–2032.
24. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, Ohishi N, Yagi K:
Arsenic trioxide-induced apoptosis through oxidative stress in cells of
colon cancer cell lines. Life Sci 2002, 70(19):2253–2269.
25. Rudolf E, Kralova V, Cervinka M: Selenium and colon cancer–from
chemoprevention to new treatment modality. Anticancer Agents Med
Chem 2008, 8(6):598–602.
26. Schroterova L, Kralova V, Voracova A, Haskova P, Rudolf E, Cervinka M:
Antiproliferative effects of selenium compounds in colon cancer cells:
comparison of different cytotoxicity assays. Toxicol In Vitro 2009,
23(7):1406–1411.
27. Abdulah R, Faried A, Kobayashi K, Yamazaki C, Suradji EW, Ito K, Suzuki K,
Murakami M, Kuwano H, Koyama H: Selenium enrichment of broccoli
sprout extract increases chemosensitivity and apoptosis of LNCaP
prostate cancer cells. BMC Cancer 2009, 9:414.
28. Peters U, Takata Y: Selenium and the prevention of prostate and
colorectal cancer. Mol Nutr Food Res 2008, 52(11):1261–1272.
29. Bastow M, Kriedt CL, Baldassare J, Shah M, Klein C: Zinc is a potential
therapeutic for chemoresistant ovarian cancer. J Exp Ther Oncol 2011,
9(3):175–181.
30. Brama M, Gnessi L, Basciani S, Cerulli N, Politi L, Spera G, Mariani S,
Migliaccio S, Scandurra R, d'Abusco AS, Cherubini S: Cadmium induces
mitogenic signaling in breast cancer cell by an ERalpha-dependent
mechanism. Mol Cell Endocrinol 2007, 264(1–2):102–108.
31. Sun L, Wu S, Coleman K, Fields KC, Humphrey LE, Brattain MG: Autocrine
transforming growth factor-beta 1 and beta 2 expression is increased by
cell crowding and quiescence in colon carcinoma cells. Exp Cell Res 1994,
214(1):215–224.
32. Gartel AL: The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in
apoptosis. Leuk Res 2005, 29(11):1237–1238.
33. Chu IM, Hengst L, Slingerland JM: The Cdk inhibitor p27 in human cancer:
prognostic potential and relevance to anticancer therapy. Nat Rev Cancer
2008, 8(4):253–267.
34. Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, Gianella-Borradori A,
Lane DP, Hubank M, Powell JE, Wei W, et al: A novel CDK inhibitor,CYC202 (R-roscovitine), overcomes the defect in p53-dependent
apoptosis in B-CLL by down-regulation of genes involved in
transcription regulation and survival. Blood 2005, 105(11):4484–4491.
35. Eskens FA, Verweij J: The clinical toxicity profile of vascular endothelial
growth factor (VEGF) and vascular endothelial growth factor receptor
(VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006,
42(18):3127–3139.
doi:10.1186/1472-6882-13-189
Cite this article as: Cho et al.: Particled Mica, STB-HO has
chemopreventive potential via G1 arrest, and inhibition of proliferation
and vascular endothelial growth factor receptor 2 in HCT colorectal
cancer cells. BMC Complementary and Alternative Medicine 2013 13:189.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
